Protalix CEO confident data submission will address US FDA concerns for Gaucher's drug
This article was originally published in Scrip
Executive Summary
Investors felt somewhat reassured that Protalix BioTherapeutics had satisfactorily dealt with requests for additional data outlined by US regulators in a February complete response letter (CRL) for the Carmiel, Israel-based firm's investigational Gaucher's disease drug taliglucerase alfa, giving the company's shares a 3.6% boost on 1 August in US trading, or 23 cents, before closing at $6.64, a gain of 20 cents, or 3.1%.